Actively Recruiting
Incidence of Liver Disease-Related Outcomes in People With HIV
Led by Shanghai Public Health Clinical Center · Updated on 2026-03-17
320
Participants Needed
2
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Antiretroviral therapy can effectively control the replication of HIV, prolong the lifespan of patients infected with HIV, and improve their quality of life.At the same time, non-AIDS-related diseases such as diabetes and chronic liver diseases are increasing day by day.Metabolic associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by overnutrition and insulin resistance in genetically susceptible individuals. It was formerly known as non-alcoholic fatty liver disease (NAFLD).With the continuous improvement of living standards and the constant change of lifestyles, the incidence of metabolic associated fatty liver disease is gradually increasing. Metabolic associated steatohepatitis (MASH) may further develop into liver cirrhosis, liver failure and hepatocellular carcinoma, and is the third most common cause of liver transplantation. In HIV patients, early identification of significant liver fibrosis and MASH with fibrosis is of vital importance.However, due to the fact that the pathogenesis of liver fibrosis in HIV patients is more complex than that in the general population, it involves multiple factors such as the virus, reverse transcriptase drugs, chronic inflammation, and immune disorders.However, the current clinical research on metabolic-related fatty liver fibrosis in people with HIV is still rather limited.
CONDITIONS
Official Title
Incidence of Liver Disease-Related Outcomes in People With HIV
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 70 years old
- Diagnosed with HIV
- Had abdominal ultrasound and Fibroscan between December 2019 and April 2020 with available LSM and CAP data
- Routine follow-up at the hospital outpatient department from April 2020 to April 2025
You will not qualify if you...
- Men consuming more than 210g of alcohol per week; women consuming more than 140g per week
- Having other liver diseases such as viral hepatitis, drug-induced liver disease, autoimmune liver disease, decompensated liver cirrhosis, liver cancer, or history of liver transplantation
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China, 201508
Not Yet Recruiting
2
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China, 201508
Actively Recruiting
Research Team
Y
Yinzhong Shen, PhD
CONTACT
W
Wei Xu, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here